BeiGene enters $400M unsecured credit facility with China Merchants Bank

BeOne Medicines Ltd.

Facility dated Dec 9, 2024; $400M uncommitted, unsecured, revolving; SOFR-based floating rate.
Proceeds for daily operations and refinancing existing working capital loans.
Company plans to repay $300M of existing $380M drawn facility in Dec 2024; remaining $80M in Jan 2025.
Covenants include liabilities-to-equity ratio, minimum consolidated net assets and cash balance tested quarterly.
No borrowings outstanding under new facility as of filing date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.